USPTO Examiner GREENE IVAN A - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18766716METHOD FOR TREATING CANCER CELLS WITH A CU/AG PARTICLE COMPOSITIONJuly 2024September 2024Allow200YesNo
18602710MULTISTAGE CALCINATION METHOD FOR MAKING HOLLOW SILICA SPHERESMarch 2024August 2024Allow510YesNo
18599582METHOD FOR DECREASING COLORECTAL CANCER CELLSMarch 2024June 2024Allow300YesNo
18545415SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NEUROTROPHIC AND NEUROPROTECTIVE COMPOSITIONSDecember 2023April 2025Abandon1610NoNo
18541054PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFDecember 2023February 2025Abandon1410NoNo
18500167PLASMONIC ENHANCED MAGNETIC NANOPARTICLES HYPERTHERMIANovember 2023October 2025Abandon2421NoNo
18374334HOLLOW SILICA SPHERES WITH NESTED IRON OXIDE PARTICLESSeptember 2023February 2024Allow410YesNo
18231862NANOCOMPOSITE COMPOSITIONS COMPRISING MULTI-VALENT METAL MATERIAL AND IMMOBILIZED QUAT MATERIAL, METHODS OF MAKING THE COMPOSITIONS AND METHODS OF USING THE COMPOSITIONSAugust 2023February 2025Abandon1810NoNo
18366927SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR PHARMACEUTICAL COMPOSITIONSAugust 2023January 2025Abandon1810NoNo
18366945SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONSAugust 2023January 2025Abandon1810NoNo
18220560COMPOSITION FOR TREATING BONE LOSSJuly 2023May 2025Abandon2340NoNo
18220599COMPOSITION FOR TREATING BONE LOSSJuly 2023January 2025Abandon1830NoNo
18349753BIOLOGICALLY ACTIVE SUBSTANCE UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAMEJuly 2023February 2025Abandon2011NoNo
18348799EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOFJuly 2023December 2025Allow2921NoNo
18343812CANCER TREATING COMPOSITION CONTAINING COPPER-SILVER-PHOSPHATE NANOPARTICLESJune 2023May 2025Allow2331YesNo
18343803COPPER-SILVER-PHOSPHATE NANOPARTICLE MANUFACTURING METHODJune 2023January 2025Allow1911NoNo
18200055HOLLOW SILICA SPHERES WITH NESTED IRON OXIDE PARTICLESMay 2023August 2024Allow1410YesNo
18301505METHOD FOR KILLING COLORECTAL CANCER CELLSApril 2023November 2024Allow1920YesNo
18025686MICROORGANISM TARGETED NANOFORMULATIONS COMPRISING ANTIMICROBIAL COMPONENT(S)March 2023March 2026Abandon3601NoNo
18025408Nanoparticles To Improve Analytical SignalMarch 2023March 2026Abandon3601NoNo
18024743LIPID NANOPARTICLES MANUFACTURING CHIP, LIPID NANOPARTICLES MANUFACTURING SYSTEM HAVING THE SAME, AND LIPID NANOPARTICLES MANUFACTURING METHODMarch 2023August 2025Allow2941YesYes
18116820COMPOSITION FOR TREATING BONE LOSSMarch 2023February 2025Abandon2441NoNo
18169051CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAMEFebruary 2023October 2024Allow2010NoNo
18020525ACTIVE AGENT RELEASE PARTICLEFebruary 2023March 2026Abandon3701NoNo
18016092VETERINARY COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF PROTOZOAN DISEASES AND METHODS OF PREPARATION THEREOFJanuary 2023November 2025Abandon3401NoNo
18087137COMPOSITE IMPLANTSDecember 2022January 2024Abandon1311NoNo
18001398NANOSPHERE SIZE CONTROL BY VARYING THE RATIO OF COPOLYMER BLENDSDecember 2022February 2026Abandon3801NoNo
18071733NANOEMULSIONNovember 2022October 2025Abandon3521NoNo
17926902COMPOSITE MATERIALNovember 2022February 2026Abandon3911NoNo
17999384METHOD OF TREATING OBESITY-INDUCED GLUCOSE INTOLERANCE AND LIVER FIBROSISNovember 2022November 2025Abandon3601NoNo
17987391UPCONVERSION NANOPARTICLE, HYALURONIC ACID-UPCONVERSION NANOPARTICLE CONJUGATE, AND A PRODUCTION METHOD THEREOF USING A CALCULATION FROM FIRST PRINCIPLESNovember 2022August 2025Abandon3321NoNo
17956887TREATMENT METHOD FOR COLON CANCERSeptember 2022April 2023Allow610NoNo
17956875TREATMENT METHOD FOR COLON CANCERSeptember 2022January 2023Allow300YesNo
17903273Liquid Foundation Using Starch as Filler and Preparation Method thereofSeptember 2022October 2025Abandon3710NoNo
17823750METHOD FOR MAKING SOLID SILICA SPHERESAugust 2022August 2024Allow2320YesNo
17893633HYBRID FRAGRANCE ENCAPSULATE FORMULATION AND METHOD FOR USING THE SAMEAugust 2022June 2025Allow3410NoNo
17821471BIOCOMPATIBLE PHOTOTHERMAL COMPOSITION FOR TREATMENT OF CANCER AND SKIN DISEASESAugust 2022July 2025Abandon3521NoNo
17800066AMPHIPHILIC IMIQUIMOD-GRAFTED LAURYL GAMMA-POLYGLUTAMATE AND USE THEREOFAugust 2022September 2025Abandon3710NoNo
17886329BIOMARKERS FOR NANOPARTICLE COMPOSITIONSAugust 2022February 2025Abandon3111NoNo
17811296METHODS FOR TREATMENT OF BLADDER CANCER WITH GEMCITABINEJuly 2022December 2025Allow4140YesYes
17855758MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIAJune 2022September 2025Abandon3920NoYes
17786678Determining Capsule Specificity for Specific Cell TypesJune 2022December 2025Abandon4211NoNo
17806839PEDIATRIC FORMULATIONJune 2022March 2024Abandon2111NoNo
17827190LIGHT-CONTROLLABLE SELF-ASSEMBLED COMPLEX AND NANOSYSTEM INCLUDING THE SAMEMay 2022December 2025Abandon4341NoNo
17748197Polymer complex for anticancer immune therapy based on ultrasound comprising oxalate derivatives and Method of preparation thereofMay 2022February 2026Abandon4551NoNo
17741464ANTIMICROBIAL NANO-DELIVERANT AND METHODSMay 2022August 2025Abandon3901NoNo
17737561NICOTINAMIDE ADENINE DINUCLEOTIDE ACTIVATOR AND USE THEREOFMay 2022October 2024Abandon3021NoNo
17661172CANNABINOID COMPOSITIONS AND PROCESSES FOR MAKING SAMEApril 2022December 2023Abandon2001NoNo
17730820COMPOSITION, PARTICULATE MATERIALS AND METHODS FOR MAKING PARTICULATE MATERIALSApril 2022June 2023Allow1400YesNo
17768132SUPERFINE COMPOUNDS AND PRODUCTION THEREOFApril 2022May 2025Abandon3741YesNo
17715970STARCH-BASED DOUBLE-LOADED FUNCTIONAL NANO PARTICLE AS WELL AS PREPARATION METHOD AND APPLICATIONApril 2022July 2024Allow2711NoNo
17711863COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERSApril 2022February 2024Allow2210NoNo
17761057BISPHOSPHONATE LOADED STARCH NANOPARTICLEMarch 2022September 2025Abandon4201NoNo
17760537HAIR TREATMENT METHODMarch 2022September 2025Abandon4220YesNo
17579087METHOD OF PREPARING NANOPARTICLES FOR CANCER TREATMENTSJanuary 2022January 2024Allow2411YesNo
17627044ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMSJanuary 2022October 2025Abandon4521NoNo
17646670HIGH-DENSITY AND SHORT-CHAIN PEG MODIFIED NANO-SIZED CARRIERS AND THEIR USESDecember 2021September 2025Abandon4531NoNo
17561540METHODS FOR TREATMENT OF BLADDER CANCER WITH GEMCITABINEDecember 2021February 2025Abandon3820YesYes
17552412PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFDecember 2021January 2024Abandon2510NoNo
17519900Esteramine CompositionsNovember 2021March 2025Abandon4101NoNo
17604138METHOD FOR REMOVING BIOFILMOctober 2021May 2025Abandon4311NoNo
17389680OPHTHALMIC COMPOSITIONS FOR REMOVING MEIBUM OR INHIBITING MEIBUM BUILDUPJuly 2021March 2025Abandon4431NoNo
17384126LASER ENHANCER COMPOSITION FOR IMPROVING MELASMA, WRINKLES, SKIN TIGHTENING, PORES, AND ACNEJuly 2021February 2024Abandon3111NoNo
17383161COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERSJuly 2021October 2025Abandon5150NoNo
17351337NANOPARTICLE-ENCAPSULATED CANNABINOIDS AND METHODS FOR MAKING AND USING SAMEJune 2021November 2024Abandon4131NoNo
17352245PREPARATION OF NANOPARTICLES USING MODIFIED ICE-TEMPLATEJune 2021February 2024Abandon3221NoNo
17332175POLY(AMINE-CO-ESTER) POLYMERIC PARTICLES FOR SELECTIVE PULMONARY DELIVERYMay 2021November 2025Abandon5441NoYes
17318339MULTI-COATED NANOPARTICLES COMPRISING MULTIPLE COATING LAYERS OF CHITOSAN AND POLYGLUTAMIC ACID, COMPOSITION FOR SKIN CARE COMPRISING THE SAME AND METHOD FOR MANUFACTURING THE SAMEMay 2021April 2025Allow4741YesNo
17306403DISSOLVING FILM FOR DELIVERY OF AN ACTIVE AGENTMay 2021October 2023Abandon3011NoNo
17244828NANOPARTICLE DELIVERY TO A TARGET TISSUEApril 2021August 2025Abandon5241NoNo
17240405Nanoparticle Depot For Controlled And Sustained Gene DeliveryApril 2021January 2025Abandon4540YesNo
17239262NANOEMULSION HYDROPHOBIC SUBSTANCESApril 2021February 2023Abandon2231YesNo
17231231METHODS OF TREATMENT USING TITANIUM AND SILVER NANOPARTICLES MADE WITH AN INTRACELLULAR EXTRACT OF FOMES FOMENTARIOUSApril 2021September 2023Abandon2921YesNo
17228224DUAL-TARGETING LIPID-POLYMER HYBRID NANOPARTICLESApril 2021November 2024Abandon4341NoNo
17205521METHOD FOR TREATMENT OF CORONAVIRUS INFECTIONMarch 2021April 2025Abandon4931NoYes
17200540Injectable Therapeutic Biocompatible Co-Polymers and Methods of Making and Using SameMarch 2021October 2025Abandon5631NoYes
17188401PHARMACEUTICAL COMPOSITIONS OF RIVAROXABANMarch 2021September 2024Abandon4331NoNo
17178808POLYMER-CYCLIC MOLECULE STRUCTURE AND METHOD FOR PRODUCING THE SAMEFebruary 2021September 2024Abandon4331YesNo
17267187INJECTABLE PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFORFebruary 2021December 2023Abandon3401NoNo
17259371A BIOLOGICALLY ACTIVE SUBSTANCE UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAMEJanuary 2021November 2023Abandon3440YesNo
17136251METAL EXTRACTION SHEET, MASK PACK INCLUDING SAME AND METHOD FOR MANUFACTURING THE METAL EXTRACTION SHEETDecember 2020August 2024Abandon4331YesNo
16973721USE OF PHOSPHORUS-BASED MATERIAL IN PREPARATION OF MEDICAMENT FOR TREATING TUMORSDecember 2020December 2024Abandon4821YesNo
17106625PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOFNovember 2020April 2022Abandon1711NoNo
17079214CANNABINOID-CONTAINING ORAL THIN FILM FORMULATIONSOctober 2020May 2022Abandon1920YesNo
17070311PLASMONIC ENHANCED MAGNETIC NANOPARTICLES HYPERTHERMIAOctober 2020December 2025Abandon6081YesNo
17067297CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAMEOctober 2020April 2023Allow3011YesNo
17041094Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of CancerSeptember 2020March 2026Abandon6061YesNo
16990634CORE-SHELL STRUCTURE, PREPARATION, MEDICINE FOR EXTERNAL APPLICATION, TAPE AGENT AND COSMETIC PRODUCTAugust 2020September 2024Allow4920YesYes
16931939PRODUCTION OF NANOPARTICLESJuly 2020May 2023Abandon3421NoNo
16932699CANNABINOID COMPOSITIONS AND PROCESSES FOR MAKING SAMEJuly 2020May 2022Abandon2231YesNo
16925478DISPERSIBLE POWDER AND COSMETICJuly 2020March 2024Abandon4430NoNo
16906028HYDROGEL INCLUSION COMPLEX INCLUDING PHYSIOLOGICALLY ACTIVE MATERIAL BOUND TO THERMOSENSITIVE POLY(PHOSPHAZENE) BY HOST-GUEST INTERACTION USING BETA-CYCLODEXTRIN AND USE THEREOFJune 2020May 2025Abandon5841NoNo
16896259Multi-Dose Concentrated Liquid Diphenhydramine HCl Compositions and Packaged Multi-Dose Liquid Diphenhydramine HCl FormulationsJune 2020November 2025Abandon6020NoYes
16890172FUNCTIONAL MEMBER AND METHOD OF FABRICATING THE SAMEJune 2020February 2023Abandon3301NoNo
16884161HIGH ABSORPTION MINERALSMay 2020February 2025Abandon5741YesNo
16880309COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTSMay 2020July 2024Abandon5040NoNo
16764551METAL-NUCLEIC ACID NANOPARTICLE, PREPARATION METHOD THEREFOR AND USE THEREOFMay 2020July 2022Allow2611YesNo
16760183RADIATION STERILIZED HYDROGELS, MEDICAL DEVICES INCLUDING RADIATION STERILIZED HYDROGELS AND METHODS OF MAKING THE SAMEApril 2020January 2025Abandon5631NoYes
16850468MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIAApril 2020March 2022Allow2310NoNo
16652944WATER-BASED TISSUE ADHESIVESApril 2020November 2025Allow6021YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GREENE, IVAN A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
51
Examiner Affirmed
35
(68.6%)
Examiner Reversed
16
(31.4%)
Reversal Percentile
47.9%
Lower than average

What This Means

With a 31.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
157
Allowed After Appeal Filing
26
(16.6%)
Not Allowed After Appeal Filing
131
(83.4%)
Filing Benefit Percentile
19.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GREENE, IVAN A - Prosecution Strategy Guide

Executive Summary

Examiner GREENE, IVAN A works in Art Unit 1619 and has examined 596 patent applications in our dataset. With an allowance rate of 17.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.

Allowance Patterns

Examiner GREENE, IVAN A's allowance rate of 17.1% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GREENE, IVAN A receive 3.26 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GREENE, IVAN A is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +6.4% benefit to allowance rate for applications examined by GREENE, IVAN A. This interview benefit is in the 33% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 3.5% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 9.2% of cases where such amendments are filed. This entry rate is in the 9% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 34.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 45.2% of appeals filed. This is in the 11% percentile among all examiners. Of these withdrawals, 21.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 62.7% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.